-
23 Juillet 2025
-
23 Juillet 2025
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:...
-
12 Janvier 2026
- 2 mn de lecture
-
12 Janvier 2026
- 2 mn de lecture
Bridging science and leadership: Elisabetta Leo on guiding early development at Ipsen
“I felt, during my career path, that I was more a scientist rather than a leader; in my current role, I’m bridging the two as a research leader.” ...
-
13 Janvier 2026
-
13 Janvier 2026
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
PARIS, FRANCE, 13 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for IPN60340 in combination with venetoclax and azacitidine (Ven-Aza) in ...
-
29 Mai 2024
- 1 min read
-
29 Mai 2024
- 1 min read
Together, we can improve the lives of people living with kidney cancer
Together for Kidney Cancer is a global disease awareness initiative funded by Ipsen aiming to raise awareness of the reality of people’s experiences living with kidney cancer and the importance of shared decision making to inform better care outcomes....
-
29 Mai 2024
- 2 mn de lecture
-
29 Mai 2024
- 2 mn de lecture
Ensemble, nous pouvons améliorer la vie des personnes atteintes d’un cancer du rein
Together for Kidney Cancer est une initiative mondiale financée par Ipsen, qui vise à sensibiliser le plus grand nombre sur la réalité du quotidien des personnes atteintes d’un cancer du rein et l’importance d’une prise de décision partagée pou...
-
13 Mars 2026
- 2 mn de lecture
-
13 Mars 2026
- 2 mn de lecture
From culture to clinic: Alison Mason on making science work at scale
“We’re doing real science. For real people. And we’re doing it together. That’s what matters most to me.” – Alison Mason ...
-
22 Décembre 2025
-
22 Décembre 2025
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC1...
-
25 Mars 2022
-
25 Mars 2022
-
13 Février 2025
-
13 Février 2025
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
PARIS, FRANCE, 13 February 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024....